Skip to main content
Advertisement
Advertisement

ALNY

ALNY logo

Alnylam Pharmaceuticals, Inc.

231.83
USD
Sponsored
-2.20
-0.94%
Oct 16, 15:59 UTC -4
Closed
exchange

After-Market

231.93

+0.09
+0.04%

ALNY Earnings Reports

Positive Surprise Ratio

ALNY beat 22 of 42 last estimates.

52%

Next Report

Date of Next Report
Oct 29, 2026
Estimate for Q3 26 (Revenue/ EPS)
$1.46B
/
$1.75
Implied change from Q2 26 (Revenue/ EPS)
+12.68%
/
+44.63%
Implied change from Q3 25 (Revenue/ EPS)
+16.73%
/
-17.06%

Alnylam Pharmaceuticals, Inc. earnings per share and revenue

On Jul 30, 2026, ALNY reported earnings of 1.21 USD per share (EPS) for Q2 26, missing the estimate of 1.58 USD, resulting in a -23.70% surprise. Revenue reached 1.29 billion, compared to an expected 1.35 billion, with a -4.14% difference. The market reacted with a -28.31% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 16 analysts forecast an EPS of 1.75 USD, with revenue projected to reach 1.46 billion USD, implying an increase of 44.63% EPS, and increase of 12.68% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Oct 12, 2026 For Q3 26
Estimate
-$0.61
Actual
$4.73
Surprise
+871.74%
FAQ
For Q2 2026, Alnylam Pharmaceuticals, Inc. reported EPS of $1.21, missing estimates by -23.7%, and revenue of $1.29B, -4.14% below expectations.
The stock price moved down -28.31%, changed from $286.62 before the earnings release to $205.48 the day after.
The next earning report is scheduled for Oct 29, 2026.
Based on 16 analysts, Alnylam Pharmaceuticals, Inc. is expected to report EPS of $1.75 and revenue of $1.46B for Q3 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement